Dr. Lin has 32 years of experience in the pharmaceutical industry from early development to product registrations and life-cycle management. Her expertise is on phase-appropriate analytical strategy, method development and validation, stability, structure elucidation, cGMP compliance, selection and management of CROs and analytical technology transfers. She is also experienced in writing CMC sections of regulatory filings and participating in FDA meetings.
Elizabeth held positions of increasing responsibility at Johnson & Johnson, Schering-Plough (now Merck), Allergan and Nektar Therapeutics. She worked on various oral and injectable dosage forms as well as drug-device combination products.
Elizabeth obtained her PhD in Organic Chemistry at the University of Washington and was a post-doctoral fellow at the Scripps Research Institute.